Phase 2Completed
A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients (LIGHT)
A Randomized, Double-Blind, Placebo-controlled Study of Efsubaglutide Alfa on Weight Management in Subjects With Overweight or Obesity to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics, and Efficacy.
- Sponsor
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. (Academic or other)
- Enrollment
- 50 enrolled
- Conditions
- Overweight or Obesity
- Interventions
- Efsubaglutide Alfa; Placebo
- Ages
- adults, older adults
- Registry
- NCT06732960
Full record on ClinicalTrials.gov
From the registry
This is a study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa at difference dose range once-weekly in patients with Overweight or Obesity.
Primary outcomes
- Weight
- Adverse Event
History
Last registry update
Registered
Primary completion
Started
Papers citing this trial
- Efficacy and Safety of Efsubaglutide Alfa in Patients with Obesity or Overweight—A Phase 2 Study
ADA Scientific Sessions 2025 abstract